INVENTORIES

9 Months Ended

Sep. 30, 2025

Inventory Disclosure [Abstract]

INVENTORIES

INVENTORIES

Inventories consist of the following as of:

(in thousands)	September 30, 2025		December 31, 2024
Raw materials	$	68,649	$	67,174
Packaging materials	9,711		9,977
Work-in-progress	5,000		1,665
Finished goods	63,115		57,966
Inventories	$	146,475	$	136,782

Vendor Concentration

Raw materials are sourced for products, including active pharmaceutical ingredients (“API”), from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the cost and time required to validate a second source of supply. As a result, the Company is dependent upon our current vendors to reliably supply the API required for on-going product manufacturing. During the three and nine months ended September 30, 2025, approximately 21% and 22%, respectively, of our raw material inventory purchases were from one domestic supplier. During the three months ended September 30, 2024, no single vendor represented more than 10% of our raw inventory purchases. During the nine months ended September 30, 2024, approximately 17% of our raw material inventory purchases were from one domestic supplier.